Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2015 2
2016 1
2017 1
2018 4
2019 3
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Among authors: vergidis j. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN. Annala M, et al. Among authors: vergidis j. Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24. Cancer Discov. 2018. PMID: 29367197 Free article. Clinical Trial.
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Khalaf DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, Ivanov N, Finch DL, Oja C, Vergidis J, Zulfiqar M, Gleave ME, Chi KN. Khalaf DJ, et al. Among authors: vergidis j. Eur Urol. 2019 Jun;75(6):940-947. doi: 10.1016/j.eururo.2018.12.015. Epub 2018 Dec 24. Eur Urol. 2019. PMID: 30591354 Clinical Trial.
Cost-effectiveness of therapies for melanoma.
Johnston KM, McPherson E, Osenenko K, Vergidis J, Levy AR, Peacock S. Johnston KM, et al. Among authors: vergidis j. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):229-42. doi: 10.1586/14737167.2015.1017563. Epub 2015 Feb 23. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25703441 Review.
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators, Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E. Khalaf DJ, et al. Among authors: vergidis j. Ann Oncol. 2020 Sep;31(9):1186-1197. doi: 10.1016/j.annonc.2020.06.006. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32574722 Clinical Trial.
Evolution of Castration-Resistant Prostate Cancer in CtDNA during Sequential Androgen Receptor Pathway Inhibition.
Annala M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, Beja K, Sipola J, Warner EW, Herberts C, Wong A, Fu S, Finch DL, Oja CD, Vergidis J, Zulfiqar M, Eigl BJ, Kollmansberger CK, Nykter M, Gleave ME, Chi KN, Wyatt AW. Annala M, et al. Among authors: vergidis j. Clin Cancer Res. 2021 Jun 3. doi: 10.1158/1078-0432.CCR-21-1625. Online ahead of print. Clin Cancer Res. 2021. PMID: 34083234
12 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page